In its SmPC (summaries of product characteristics), Ranbaxy states that there is a non-negligible risk of medical abortion treatment failure, as follows:
The non-negligible risk of failure, which occurs in 4.5 to 7.8% of the cases, makes the follow-up visit mandatory in order to check that abortion is complete. The patient should be informed that surgical treatment may be required to achieve complete abortion.
Discover more from Percuity
Subscribe to get the latest posts sent to your email.
